Evidence map›Paper›PMID 25375886›Full record

ArticlePloS one2014

In vitro, in silico and in vivo studies of ursolic acid as an anti-filarial agent.

Komal Kalani, Vikas Kushwaha, Pooja Sharma, Richa Verma, Mukesh Srivastava, Feroz Khan, P K Murthy, Santosh Kumar Srivastava

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. An Inventory of Anthelmintic Plants across the Globe.Pathogens (Basel, Switzerland) · 2023
    Review
  6. Article
  7. The potentials ofJournal of parasitic diseases : official organ of the Indian Society for Parasitology · 2022
    Article
  8. Article
  9. In-vitro and in silico efficacy of isolated alkaloid compounds fromJournal of parasitic diseases : official organ of the Indian Society for Parasitology · 2019
    Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Komal KalaniMedicinal Chemistry Department, CSIR-Central Institute of Medicinal and Aromatic Plants, Lucknow, 226015 (U.P.) India; Academy of Scientific and Innovative Research (AcSIR), Anusandhan Bhawan, New Delhi, 110 001, India.
Vikas KushwahaDivision of Parasitology, CSIR-Central Drug Research Institute, Lucknow, 226001, UP, India.
Pooja SharmaMetabolic & Structural Biology Department, CSIR-Central Institute of Medicinal and Aromatic Plants, Lucknow, 226015 (U.P.) India.
Richa VermaDivision of Parasitology, CSIR-Central Drug Research Institute, Lucknow, 226001, UP, India.
Mukesh SrivastavaClinical and Experimental Medicine, Biometry section, CSIR-Central Drug Research Institute, Lucknow, 226001, UP, India.
Feroz KhanMetabolic & Structural Biology Department, CSIR-Central Institute of Medicinal and Aromatic Plants, Lucknow, 226015 (U.P.) India; Academy of Scientific and Innovative Research (AcSIR), Anusandhan Bhawan, New Delhi, 110 001, India.
P K MurthyDivision of Parasitology, CSIR-Central Drug Research Institute, Lucknow, 226001, UP, India.
Santosh Kumar SrivastavaMedicinal Chemistry Department, CSIR-Central Institute of Medicinal and Aromatic Plants, Lucknow, 226015 (U.P.) India; Academy of Scientific and Innovative Research (AcSIR), Anusandhan Bhawan, New Delhi, 110 001, India.
Central Drug Research Institute · INCentral Institute of Medicinal and Aromatic Plants · INAcademy of Scientific and Innovative Research · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As part of our drug discovery program for anti-filarial agents from Indian medicinal plants, leaves of Eucalyptus tereticornis were chemically investigated, which resulted in the isolation and characterization of an anti-filarial agent, ursolic acid (UA) as a major constituent. Antifilarial activity of UA against the human lymphatic filarial parasite Brugia malayi using in vitro and in vivo assays, and in silico docking search on glutathione-s-transferase (GST) parasitic enzyme were carried out. The UA was lethal to microfilariae (mf; LC100: 50; IC50: 8.84 µM) and female adult worms (LC100: 100; IC50: 35.36 µM) as observed by motility assay; it exerted 86% inhibition in MTT reduction potential of the adult parasites. The selectivity index (SI) of UA for the parasites was found safe. This was supported by the molecular docking studies, which showed adequate docking (LibDock) scores for UA (-8.6) with respect to the standard antifilarial drugs, ivermectin (IVM -8.4) and diethylcarbamazine (DEC-C -4.6) on glutathione-s-transferase enzyme. Further, in silico pharmacokinetic and drug-likeness studies showed that UA possesses drug-like properties. Furthermore, UA was evaluated in vivo in B. malayi-M. coucha model (natural infection), which showed 54% macrofilaricidal activity, 56% female worm sterility and almost unchanged microfilaraemia maintained throughout observation period with no adverse effect on the host. Thus, in conclusion in vitro, in silico and in vivo results indicate that UA is a promising, inexpensive, widely available natural lead, which can be designed and developed into a macrofilaricidal drug. To the best of our knowledge this is the first ever report on the anti-filarial potential of UA from E. tereticornis, which is in full agreement with the Thomson Reuter's 'Metadrug' tool screening predictions.

Indexed as

Plant LeavesPlants, MedicinalAnimalsBrugia malayiComputer SimulationFilariasisFilaricidesHumansIn Vitro TechniquesTriterpenesUrsolic AcidFilaricidesTriterpenesUrsolic Acid

Identifiers

PMID25375886
PMCPMC4222910
OpenAlexW2092098513

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.